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2ABSTRACT
The potential to differentiate human embryonic stem cells (hESCs) in vitro to provide 
an unlimited source of human hepatocytes for use in biomedical research, drug 
discovery and the treatment of liver diseases holds great promise.  Here we describe a 
three-stage process for the efficient and reproducible differentiation of hESCs to 
hepatocytes by priming hESCs towards definitive endoderm with Activin A and 
Sodium Butyrate prior to further differentiation to hepatocytes with dimethyl 
sulfoxide (DMSO) followed by maturation with hepatocyte growth factor (HGF) and 
oncostatin M.  We have demonstrated that differentiation of hESCs in this process 
recapitulates liver development in vivo: following initial differentiation, hESCs 
transiently express characteristic markers of the primitive streak mesendoderm before 
turning to the markers of the definitive endoderm; with further differentiation, 
expression of hepatocyte progenitor cell markers and mature hepatocytes markers 
emerged sequentially. Furthermore, we have provided evidence that the hESC-derived 
hepatocytes are able to carry out a range of hepatocyte functions: storage of glycogen, 
generation and secretion of plasma proteins. More importantly, the hESC-derived 
hepatocytes express several members of cytochrome P450 isozymes and these P450 
isozymes are capable of converting the substrates to metabolites and respond to the 
chemical stimulation. Our results have provide evidence that hESCs can be 
differentiated efficiently in vitro to functional hepatocytes, which maybe useful as a in 
vitro system for toxicity screening  in drug discovery.
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3INTRODUCTION
Human embryonic stem cells (hESCs) are able to replicate indefinitely and to 
differentiate into most, if not all, cell types of the body, thereby having the potential to
provide an unlimited source of cells for a variety of applications. These include
regenerative medicine for a broad spectrum of human diseases, elucidating 
mechanisms underlying cell fate specification and as in vitro models for determining 
the metabolic and toxicological properties of drug compounds [1, 2]. Many of these 
applications require efficient and regulated differentiation of hESCs to specific cell 
types. Hepatocytes, the primary cells of the liver, have attracted particular attention as 
the liver plays a central role in multiple functions of the human body and liver failure 
is often only treatable by liver transplantation. Unfortunately, the number of donors is 
insufficient to cope with the growing demand for transplantation. Hepatocyte 
transplantation, to increase the number of functional hepatocytes, could be employed 
as an alternative therapeutic approach to whole organ transplantation for liver failure.
Stem cell-derived hepatocytes could also be utilised for extra-corporeal support 
devices in the case of acute liver failure [3]. In addition to their therapeutic potential, 
human hepatocytes are valuable for assessing the toxicity of new drugs, as liver is the 
primary tissue involved in the metabolism of drug compounds and is among the most 
common tissues affected by drug toxicities. Primary human hepatocytes suffer from 
not only inconsistent availability but also significant phenotypic and genotypic 
variability. Although animal models have wide application in preclinical drug 
development they are often not predictive for man.
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4Several studies have reported the differentiation of hepatocyte-like cells from human 
embryonic stem cells [4-6]. However, these papers have mainly focused on 
characterizing the final hESC-derived hepatocytes and lack of evidence that 
hepatocyte differentiation followed the liver developmental process in vivo.  The liver, 
similar to the pancreas, develops from the primitive gut tube which is formed by a flat 
sheet of cells, called definitive endoderm [5, 7]. Definitive endoderm is one of the 
three germ layers derived from the epiblast of the inner cell mass of the blastocyst and
is generated during the gastrulation stage of embryogenesis. During gastrulation, cells 
from specific regions of the epiblast are recruited to form the primitive streak where 
they transform and give rise to both mesoderm and definitive endoderm [8, 9]. The 
definitive endoderm at the anterior ventral segment of the gut tube interacting with 
cardiogenic mesoderm becomes more proliferative and forms the liver bud where 
cells are referred to as hepatoblasts [10, 11]. The hepatoblasts proceed through a 
series of maturation steps which accompany autonomous proliferation, cellular 
enlargement and functional maturation as the liver develops. During this process, cells 
express certain characteristic genes which represent cellular development with the 
primitive streak and definitive markers at early developmental stages being replaced 
by hepatic markers at later stages.
After the emergence of the liver bud from the developing gut tube, the level of hepatic 
maturation is characterized by the expression of liver- and stage-specific genes [12]. 
For example, alpha-fetoprotein (AFP) is an early hepatic marker, expressed by 
hepatoblasts in the liver bud until birth, when expression is dramatically reduced [13]. 
In contrast, albumin, the most abundant protein synthesized by hepatocytes, is initially 
expressed at lower levels in early fetal hepatocytes but this increases as the 
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5hepatocytes mature, reaching a maximum in adult hepatocytes [14]. Furthermore, 
isoforms of cytochrome P450s (CYPs) proteins also exhibit differential expression 
levels according to developmental stages of the liver. CYP3A7 is mainly expressed in 
human fetal liver while CYP3A4 is the predominant isoform in adult hepatocytes [15]. 
Previously we developed a method to differentiate hESCs to hepatocyte-like cells [16].
In the present study, we have improved the procedure further and have significantly 
increased hepatocyte production from hESCs. We show that by priming hESCs to 
differentiate through the primitive streak mesendoderm to definitive endoderm prior 
to treatment with DMSO increases the proportion of hepatocytes in the end population 
to approximately 70%.  Furthermore, we show that the gene expression profile during 
this differentiation process recapitulates that of in vivo development and the derived 
hepatocytes performed multiple liver functions.  
MATERIALS AND METHODS
Cell culture and differentiation
Human embryonic stem cells H1 and H7 were cultured and propagated in matrigel 
coated plates with mouse embryonic fibroblast conditioned medium (MEF-CM) 
supplemented with basic fibroblast growth factor in feeder-free, serum-free conditions 
as previously described [17-19]. 
The differentiation was initiated, when hESCs reached a confluence level of 
approximately 50-70%, by replacing the MEF-CM with priming medium A 
(RPMI1640 containing 1x B27 (both from Invitrogen), 1mM sodium butyrate (NaB, 
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6Sigma) and 100ng/ml activin A (PeproTech)). After 24-48 hours, the medium was 
changed to priming medium B which is the same as priming medium A, except the 
concentration of sodium butyrate was reduced to 0.5mM and cells were cultured for a 
further 48-72 hours. The cells were then split 1:2 to new matrigel coated plates and 
cultured in differentiation medium (SR/DMSO medium: knockout-DMEM containing 
20% serum replacement (SR), 1mM glutamine, 1% non-essential amino acids, 0.1mM 
-mercaptoethanol (all from Invitrogen) and 1% dimethyl sulfoxide (DMSO, Sigma)),
for 7 days. Finally, the cells were cultured in maturation medium (CL15 medium [20]: 
L15 medium supplemented with 8.3% fetal bovine serum, 8.3% tryptose phosphate 
broth, 10µM Hydrocortisone 21-hemisuccinate, 1µM insulin (all from Sigma) and 
2mM glutamine) containing 10ng/ml hepatocyte growth factor (HGF) and 20ng/ml 
oncostatin M (both from R&D systems). The medium was changed daily during 
differentiation.
RNA isolation and reverse transcription–polymerase chain reaction
Total RNA was isolated using RNeasy mini kit (Qiagen) following manufacturer’s 
instruction and DNA was removed by the treatment with DNase (Qiagen). cDNA was 
synthesised using 2µg total RNA with reverse transcriptase (Roche) in a 20-25µl 
volume. PCR was carried out as previously described [21]. Primer sequences and 
PCR conditions are provided in supplemental data Table 1. 
Immunoblotting, immunocytochemistry and flow cytometry
Cells were lysed and sonicated in sodium dodecyl sulphate (SDS) buffer and the 
lysates were separated in 8% polyacrylamide gels containing SDS, then transferred to 
nitrocellulose membrane. Western blotting was carried out as previously described 
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7[16]. For immunostaining, cells were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature and washed with PBS. After blocking with PBS containing 10% 
goat serum, cells were incubated with primary antibody at 4°C overnight, followed by 
30 minutes incubation with appropriate secondary antibody at room temperature. The 
primary and secondary antibodies used are commercially available except CYP3A 
and CYP2D6 which are from Prof. R. Wolf’s laboratory. For flow cytometry, cells 
were harvested and incubated in blocking buffer containing 40% goat serum for 30 
minutes followed by incubation with CXCR4-PE antibody following manufacturer’s 
instruction. The cells were analysed in Beckon Dickinson flow cytometer after 
washing. All the antibodies and conditions are listed in supplemental data Table 2.
The controls were performed by replacing the primary antibodies with corresponding 
IgG antibodies and they were negative. The counting on albumin and Hepar 1 staining 
were done on 300-400 cells in 4 random chosen fields. 
Measurement of hepatocyte export proteins 
Cells were cultured in 6-well plate in 3ml appropriate media and after 24 hours 
supernatants were collected for export protein assay. The hepatic export proteins 
alpha-2-macroglobulin (A2M), haptoglobin, fibrinogen and fibronectin were 
measured using sandwich enzyme-linked immunosorbent assays (ELISA) essentially 
as described by the manufacturer (DAKO, Ely, UK). High binding EIA plates 
(Corning, Koolhovenlann, Netherlands) were coated with rabbit anti-human antibody 
(DAKO, Ely, UK) to each specific protein overnight at 4°C. Antibodies were diluted 
1:1000 for A2M and fibronectin, 1:2000 for haptoglobin and 1:10000 for fibrinogen. 
Sample supernatants were diluted 1:10 and then added to 96-well plate in triplicates. 
The plates were incubated for 2 hours at room temperature. Peroxidase-conjugated 
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8rabbit anti-human antibody (DAKO) directed against the appropriate protein was 
added and the plates were incubated for 1 hour at room temperature. The substrate o-
phenylenediamine (OPD) was added and the reaction stopped with 0.5M sulphuric 
acid. The plates were read at 490 nm with a reference wavelength of 630nm using a 
MRX II plate reader (Dynatech, Billinghurst, UK) and the concentration of the 
appropriate protein in each sample was calculated from standard curves using the 
MRX II Endpoint software. Analysis of significance between variables was 
performed using the paired two-tailed t-test. A difference was considered significant 
using 95% confidence intervals (P<0.05).
Measurement of basal metabolism
hESC-derived hepatocytes and HepG2 cells (ECACC no 85011430) were incubated 
with a cocktail of midazolam, bufuralol, phenacetin and tolbutamide, each at a final 
concentration of 10µM except tolbutamide which was at 100µM in the culture 
medium.  After 24 hours, medium was collected and treated with acetonitrile to 
prevent further enzyme activity. The concentration of the metabolites, 1’-
hydroxymidazolam, 1’-hydroxybufuralol, acetaminophen and 4’hydroxytolbutamide,
were measured using reverse phase HPLC with tandem mass spectrometric detection 
(LC-MS/MS) and the amounts were calculated according to the standards which were 
prepared 0-500ng/ml in the same culture medium.  All the P450 substrates and 
metabolites were obtained from Ultrafine Chemicals or Sigma-Aldrich. The 
metabolites were normalised over alanine aminotransferase (ALT) activity which was 
measured from cell lysates using a Cobas Integra 400 clinical analyzer (Roche) and an 
in vitro diagnostic reagent system for ALT.  
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9CYP3A4 induction
Triplicate T25 flasks of hESC-derived hepatocytes as well as HepG2 cells were 
treated with rifampicin at a final concentration of 25µM or DMSO for 72 hours.  The 
rifampicin-containing medium was replaced with medium containing CYP3A4 
substrate midazolam at concentration of 10µM.  After 24 hours, medium was 
collected and 1’-hydroxymidazolam metabolite was measured with LC-MS/MS as 
described above.
RESULTS
Directed hepatocyte differentiation from hESCs
We have developed a three-step protocol by modifying our previous method [16] to 
maximize hepatocyte production from hESCs (Fig.1A and Methods). In this protocol,
hESCs, routinely cultured without feeder cells as described previously [18], were first 
treated with 100ng/ml activin A and 1 mM NaB for 24-48 hours, followed by 2-3 
days of 100ng/ml activin A and 0.5 mM NaB. During the first 24-hour period, we 
observed dramatic cell death, the surviving cells proliferated well, reaching about
70% confluence by the end of the priming stage (Fig.1A). The cells were then split at 
a 1:2 ratio and cultured in unconditioned ES medium supplemented with 1% DMSO 
for 7 days. The cells gradually exhibited morphological change from a spiky shape to 
a polygonal outline (Fig. 1B). Finally, the medium was changed to modified L15 
medium (see Methods for details) supplemented with 10ng/ml hepatocyte growth 
factor (HGF) and 20ng/ml oncostatin M (OSM) for a further 7 days. During the
differentiation process, the hESCs went through a series of profound morphological 
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10
changes and hepatocyte morphology started emerging from day 9. By day 13, the 
cells revealed characteristic hepatocyte morphology: polygonal in shape and distinct 
round nuclei (Fig. 1B & Suppl. Fig.7A). 
Direct comparison of this protocol with the previous one showed that the priming
protocol significantly increased the production of hepatocyte-like cells from about 
10% to 70%. The percentage of hepatocytes differentiated from hES cells using this 
protocol was estimated at 71% (± 7.5%) of all cells by counting albumin positive cells 
and 65% (±7.1%) of all cells by counting hepatocyte specific marker, Hepar1 positive 
cells at day 17 of differentiation. The remaining 30% cells were mainly fibroblast-like 
cells. The hESC-derived hepatocytes could be maintained in the final stage culture 
conditions for up to 5 days after characteristic hepatocyte morphology appeared, after 
which they began to deteriorate with increasing numbers of fibre-like cells (Suppl. Fig. 
7B). The time taken for the hES cell-derived hepatocytes to deteriorate in culture is 
very similar to that observed for primary human hepatocytes. 
Gene expression pattern during differentiation from hESCs to hepatocytes
reflects the progress of liver development in vivo.
Gene expression analysis showed that the expression of genes during the 
differentiation process of hESCs recapitulated that of the liver developmental process 
in vivo (Fig.2A-C and suppl Fig.8). In the first priming stage of differentiation, hESCs
were transitioned through mesendoderm to definitive endoderm. This is represented
by transient upregulation of brachyury, the gene expressed by the primitive streak 
mesendoderm and downregulated in definitive endoderm; persistent expression of 
goosecoid (GSC), CXCR4 and hepatocyte nuclear factor 3 beta (FoxA2), genes which 
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11
are expressed by the primitive streak but continuously expressed by the definitive 
endoderm progenitors [8, 22]; and increased expression of Sox17, a definitive 
endoderm marker.  Following transfer to SR/DMSO medium in stage 2 of 
differentiation, hepatocyte nuclear factor 4 (HNF4), 1 (HNF1) and 1 (HNF1) 
were dramatically upregulated, followed by increased expression of transthyretin
(TTR) which is controlled by HNF4 [23]. Towards the end of stage 2, high
expression of -fetoprotein was evident, indicating hepatoblast or early hepatocyte
formation [24]. By stage 3, expression of albumin, the most abundant protein in the 
liver, was significantly increased and maintained. Other proteins related to liver
functions were also expressed at this stage, such as apolipoprotein F (ApoF), 
constitutive androstane receptor (CAR) and tryptophan dioxygenase (TO). Up-
regulation of tyrosine aminotransferase (TAT) and CYP7A1 (Suppl. Fig. 9) in the 
hESC-derived hepatocytes indicates the hESCs were differentiated to heptic cell fate 
rather than yolk sac cells [25]. There was no clear Pax6 expression after the 
differentiation, indicating no neural ectoderm differentiated.
The gene expression pattern was further analysed by western blot. The results of
western blotting (Fig. 2B) confirmed the progression of gene expression detected by 
RT-PCR. Oct4 protein was considerably downregulated after 1 day differentiation and
became undetectable at stage 2 of the differentiation. FoxA2 was clearly upregulated 
early around day 2 of differentiation and HNF4 was present at high levels from day 
5 of stage 2. The early hepatocyte gene, AFP, appeared near the end of stage 2 and the 
more mature marker albumin was expressed at the beginning of stage 3. By stage 3, 
the hepatocyte-like cells also expressed increasing levels of c-met, the HGF receptor.
In general, expression of mRNAs and proteins showed same pattern. The subtle 
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differences between RT-PCR and western blot on HNF4 and albumin mainly reflect 
sensitivity difference between the two techniques. 
Immunostaining further confirmed the specificity of gene expression. During stage 1
differentiation, CXCR4 expressing cells increased significantly from less than 15% 
before differentiation to over 70% at end of stage 1, which is similar as reported (Fig. 
2D) [26]. The transcription factors FoxA2 and HNF4 were localised in the nuclei,
and AFP, albumin, and hepar1 showed cytoplasmic staining (Fig. 3A). The hESC-
derived hepatocytes were also stained positive for aminopeptidase N (CD13) which 
has been reported to be positive for canaculi [27]. When stained with cytokeratin 
antibodies, CK18 and CK19, most of the hESC-derived hepatocytes were positive 
(Fig. 3B).
Activin A and sodium butyrate co-operate to increase hepatocyte production 
from hESCs
In our previous method, we applied the SR/DMSO directly on hESCs to induce
differentiation [16]. The resulting hepatocytes exhibited typical polygonal 
morphology and performed a range of hepatocyte functions. However, the percentage 
of hepatocytes in the population was low, with approximately 10% of the cells 
developing hepatocyte morphology, the rest of the cells were of mixed cell types, 
indicating that differentiation induced by DMSO is not lineage-specific. We proposed 
that priming hESC differentiation to definitive endoderm prior to DMSO treatment
would be crucial in leading to more efficient hepatocyte differentiation. Increasing 
evidence show that activin/nodal signalling pathway are important for definitive 
endoderm differentiation [28-30]. Sodium butyrate (NaB) has been reported to 
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contribute to more homogeneous hepatocyte differentiation [4] and more recently, 
NaB and activin A together are found to induce definitive endoderm differentiation 
from hESCs [31] . In order to further investigate the role of activin A and NaB in the 
definitive endoderm differentiation, the hESCs (both H7 and H1) were treated with 
activin A or NaB alone or with both. After the first 24 hours of treatment, the later 
two conditions displayed substantial levels of cell death. Therefore, the NaB was 
reduced to 0.5mM for a further two days before replaced by DMSO containing 
medium. At this point, the cells from all of these treatments displayed similar 
morphologies. However, after 4 days culture in DMSO containing medium, the cells 
exhibited different changes in morphology. A considerable number of the cells in 
activin/NaB combined treatment had revealed early hepatocyte morphology, while 
cells treated with activin alone resulted in less hepatocyte formation and no clear
hepatocyte differentiation was observed in NaB treatment (Fig. 4A). 
The profile of gene expression was analysed throughout the first three days and was 
very similar between the combined and activin alone treatments, but different from 
NaB treatment (Fig. 4B). The former showed primitive streak and definitive 
endoderm markers expression, such as mixL1 GSC, Sox17 and FoxA2, which are 
very low or absent in NaB alone treated cells. However, the undifferentiation marker 
gene nanog had obvious higher expression in activin alone treated cells than those
treated with combined activin and NaB, indicating that in the current conditions 
activin alone treatment for 3 days contained more undifferentiated cells which may 
result in more heterogeneous population after further differentiation with DMSO.
Liver function in hESC-derived hepatocytes
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To test the functionality of hESC-derived hepatocytes, we carried out several 
experiments. One of the functions of the liver is its production and export of plasma 
proteins which are important in maintaining homeostasis of the body. In addition to 
albumin, other proteins include fibrinogen, a zymogen of fibrin which is important for 
blood clotting function; fibronectin, an important extracellular protein capable of 
binding receptor proteins, and alpha-2 macroglobulin (A2M), a multifunctional 
binding protein. To examine if the hESC-derived hepatocytes were capable of 
synthesizing and releasing these proteins into the culture medium, we measured these 
proteins in the culture medium by enzyme-linked immnosorbent assay (ELISA) 
during the stage 3 when early hepatocytes had formed. The data clearly show that 
these export proteins were significantly increased in the culture medium in 
comparison with hESC controls and the production of these proteins peaked at the 
later stages of the differentiation protocol when the hESC-derived hepatocytes were 
more mature (Fig. 5A).
Another important function of liver is metabolism and detoxification, in which P450 
cytochrome enzymes (CYPs) play a critical role. Thus, we examined expression of 
several members of this multigene family, including CYP3A4, CYP3A7, CYP2D6, 
CYP2C9 and CYP2C19 in the hESC-derived hepatocytes either by RT-PCR or 
western blotting. The western blotting results showed a marked increase in the 
expression of CYP3A and CYP2D6 proteins after hESCs were differentiated to 
hepatocytes (Fig. 6A). The CYP3A expression was also detected by immunostaining 
(Fig. 5B). The RT-PCR showed that both CYP3A4 and CYP3A7 were expressed in 
hESC-derived hepatocytes and the specificity and fidelity of CYP3A4 and CYP3A7 
PCR products was confirmed by sequencing (Fig. 6B). The expression levels of 
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CYP3A4 in the hESC-derived hepatocytes was similar to that observed in fetal liver 
tissues but lower than in adult liver and the CYP3A7 expression was lower than in
fetal tissues. We also detected CYP2C9 and CYP2C19 expression in the hESC-
derived hepatocytes though the levels were lower than in adult liver tissues. In 
addition to the P450 isozymes, the expression of the cytochrome P450 reductase
(CPR), an important redox partner for all CYPs, and expression of pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR), nuclear receptors
important for the transcriptional regulation of P450s and other drug metabolising 
enzymes [32] (particularly CYP3A4 and CYP2B6) in the presence of foreign toxic 
substances, were clearly induced in the hESC-derived hepatocytes after differentiation
(Figs. 5B, 2A and 6B respectively). 
To determine the activity of P450 isozymes, we measured the metabolism of the P450 
substrates midazolam, tolbutamide, bufuralol and phenacetin by measuring the 
formation of their metabolites after 24 hours. CYP3A4 metabolises midazolam to 
1’hydroxymidazolam while the metabolism of tolbutamide to 4’hydroxytolbutamide 
is catalysed by CYP2C9.  Phenacetin is converted to acetaminophen by CYP1A2 or 
CYP2E1 and bufuralol is metabolized to 1’hydroxybufuralol by CYP2D6. The 
metabolites of all substrates were detected in hESC-derived hepatocytes (Fig, 6C), 
which demonstrated that the P450 isozymes expressed in these cells are active.  When 
compared to the most commonly used human hepatocyte cell line, HepG2, the hESC-
derived hepatocytes showed considerably higher rates of metabolism of midazolam 
and tolbutamide. The tolbutamide metabolism was not detected in HepG2 cells. We 
further tested the induction of CYP3A4 upon chemical stimulation since it is the most 
prevalent P450 isozyme in adult liver and is involved in the metabolism of a 
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significant proportion of currently used drugs [33]. Since the human form of CYP3A4
can be induced with rifampicin through the transcription factor PXR, we treated both 
hESC-derived hepatocytes and HepG2 cells with rifampicin for 72 hours followed by
treatment with CYP3A4 substrate, midazolam, and the formation of
1’hydroxymidazolam was measured by mass spectrometry. hESC-derived hepatocytes 
produced higher levels of metabolites in response to rifampicin treatment although the 
increase was less than 2 fold (Fig. 6D). This suggests that the hESC-derived 
hepatocytes do respond to chemical treatment and that PXR is active in these cells.
We also examined the glycogen storage function in the hESC-derived hepatocytes 
using Periodic Acid Schiff (PAS) staining. In compare with fibroblast (Suppl. Fig. 
7B), the hESC-derived hepatocytes exhibited evident glycogen storage (Fig.5B).
DISCUSSION
We have developed a new differentiation protocol based on our previous one for 
efficient differentiation of hepatocytes from human ES cells. Direct comparison of the 
two protocols showed that activin priming protocol exhibited significant increase in 
the number of hepatocyte-like cells (70%) in compare with the previous protocol 
(10%) though hepatocytes derived from both protocols showed similar gene 
expression pattern (Fig. 2 and [16]). However, due to the low efficiency, we were 
unable to carry more detailed analysis on previous differentiation as we had to dissect 
hepatocyte foci for RT-PCR. With current protocol, we were able to extract RNA and 
protein from whole cell population and performed gene expression analysis during the 
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differentiation. The results indicated that gene expression in the current in vitro
differentiation process from ES cells to hepatocytes recapitulates liver development in 
vivo. This in vitro model, therefore, will be useful for future studies to elucidate 
molecular mechanisms regulating hepatocyte differentiation/liver development. In 
stage 1, the hESCs first converted to cells similar to the primitive streak mesendoderm 
cells, then to the cells resembling those in the definitive endoderm. This was 
characterised by the gradual downregulation of undifferentiated gene expression, such 
as Oct4 and nanog, transient increase of brachyury expression and upregulation of
GSC, Sox17 and FoxA2 expression. During stage 2 of differentiation, the definitive 
endoderm cells further differentiated to hepatocyte progenitor cells as shown by the 
gradual sequential upregulation of HNF4a, AFP and AAT. In addition, the cell 
morphology changed from a triangular spiky shape to the characteristic polygonal 
shape. Finally in the stage 3 of differentiation, the heypatocyte progenitor cells further 
developed into more mature hepatocytes as shown by the increasing expression of 
albumin, apolipoprotein F, CAR, TO and c-met receptor; evident glycogen storage 
and generation and secretion of plasma proteins. The cells exhibited characteristic 
morphology of the liver hepatocytes.
In addition, by the end of stage 3, the hESC-derived hepatocytes also expressed 
NADPH-cytochrome P450 oxidoreductase (CPR), several cytochrome P450s and
pregnane X receptor (PXR). Moreover, not only are the P450 enzymes expressed but 
also they could convert substrates to metabolites more efficiently than HepG2 cells. 
We are interested in CYP3A family members, particularly CYP3A4 as it is critical for 
the drug metabolism [33]. The hESC-derived hepatocytes expressed detectable levels 
of both CYP3A4 and CYP3A7 and responded to rifampicin treatment. This has
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important implications for the application of hESC-derived hepatocytes as an in vitro
model for drug development. Since it is very difficult to obtain human liver tissues, 
we were unable to directly compare our hESC-derived hepatocytes to primary human 
hepatocytes on the functionality tests. However, from the gene expression analysis, 
we think that to be able to use hESC-derived hepatocytes for drug screening, further 
improvement may be required, particularly on maturation. The current protocol has 
significantly improved differentiation efficiency but the hESC-derived hepatocytes
are probably still at fetal liver developmental stage as indicated by high expression of 
AFP and low expression of Cyp3A4. It remains a challenge on how to further mature 
hESC-derived hepatocytes. Liver development in vivo occurs in a 3-dimensional (3D) 
environment but in vitro culture is 2-dimensional (2D). Although this 2D system may 
aid efficient differentiation of hESCs to hepatocytes as cells receive more
synchronous induction, the 3D culture environment promotes cell-cell interactions
which may further enhance maturation and function [34, 35]. In addition, the current 
culture conditions may not be ideal for further hepatocytes maturation. We have 
changed maturation medium from hepatocyte culture medium [16] to the current 
modified L15 medium which has reduced appearance of vacuole-like structures in 
maturing hepatocytes and proliferation of non-hepatocytes, mainly fibroblasts. Further 
improvements of the culture conditions may help further maturation and enhance 
functionality. Moreover, although the majority of the cells in the liver are hepatocytes, 
the liver also contains other cell types, such as Kupffer cells, liver endothelial cells, 
etc. These cells may have an effect on hepatocyte maturation and liver function.
Future work on maturation will need to take these factors into account.
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In our differentiation protocol, the combination of activin A and NaB treatment
primes hESCs more efficiently after further differentiation to hepatocytes than the 
activin A alone. However, when we checked the gene expression patterns after stage 1
in both H1 and H7 cells, the activin A only treated group seemed to have higher 
expression of the definitive endoderm markers (e.g. Sox17, FoxA2) and NaB itself 
did not show any evidence of promoting hESCs to the definitive endoderm. This 
raises the question of the role of NaB in this process. NaB, a short-chain fatty acid, is 
a histone deacetylase (HDAC) inhibitor and has been reported to induce growth arrest, 
differentiation and apoptosis in a number of cancer cells [36, 37]. Since NaB and the 
combined treatment resulted in more cell death than activin A alone in our 
experiments, we hypothesised that NaB functions as a selecting reagent to ablate 
those cells which do not differentiate. The expression of nanog in these three 
treatments supported this postulation. After three days of treatment, the cells treated 
with activin A alone expressed the highest levels of nanog relative to cells treated 
with NaB alone or a combination of these treatments.  These data indicate that after 3 
days of activin A treatment, a subset of undifferentiated hESCs remain which account 
for the formation of other cell types after DMSO treatment (DMSO does not 
specifically direct hESCs to the definitive endoderm lineage). More recently, a three-
step protocol has been developed in which a 70% hepatocyte yield was achieved [38]
using activin A alone in the first stage. This difference to our results may be a 
consequence of the different reagents used in the second stage.
Protocols which direct hESCs down specific differentiation pathways efficiently are
important for biomedical as well as regenerative medical applications. Here we report
a simple and relatively economical strategy to differentiate hESCs efficiently to 
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hepatocytes.  This system will be very useful in the further development of using 
hESC-derived hepatocytes for biomedical and clinical research and application.
ACKNOWLEDGEMENTS
We thank Anish Majumdar and Jianjie Jiang from Geron Corporation for their 
technical help and discussion at early stage of the project; other members of the 
laboratories who have provided assistance through-out this project. This work was 
sponsored by Geron Corporation, California USA, the Biotechnology and Biological 
Science Research Council (BBSRC) and Institute of Obstetrics and Gynaecology 
Trust.
REFERENCES
1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines 
derived from human blastocysts. Science  1998;282:1145-1147
2. Reubinoff BE, Pera MF, Fong CY, et al. Embryonic stem cell lines from 
human blastocysts: somatic differentiation in vitro. Nat Biotechnol 
2000;18:399-404
3. Soto-Gutierrez A, Kobayashi N, Rivas-Carrillo JD, et al. Reversal of mouse 
hepatic failure using an implanted liver-assist device containing ES cell-
derived hepatocytes. Nat Biotechnol 2006;24:1412-1419
Page 20 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21
4. Rambhatla L, Chiu CP, Kundu P, et al. Generation of hepatocyte-like cells 
from human embryonic stem cells. Cell Transplant 2003;12:1-11
5. Lavon N, Yanuka O, Benvenisty N. Differentiation and isolation of hepatic-
like cells from human embryonic stem cells. Differentiation 2004;72:230-238
6. Schwartz RE, Linehan JL, Painschab MS, et al. Defined conditions for 
development of functional hepatic cells from human embryonic stem cells. 
Stem Cells Dev 2005;14:643-655
7. Wells JM, Melton DA. Vertebrate endoderm development. Annu Rev Cell 
Dev Biol 1999;15:393-410
8. Tada S, Era T, Furusawa C, et al. Characterization of mesendoderm: a 
diverging point of the definitive endoderm and mesoderm in embryonic stem 
cell differentiation culture. Development 2005;132:4363-4374
9. Kubo A, Shinozaki K, Shannon JM, et al. Development of definitive 
endoderm from embryonic stem cells in culture. Development 2004;131:1651-
1662
10. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell 
lineage control, and morphogenesis. Curr Opin Genet Dev 2004;14:582-590
11. Gouon-Evans V, Boussemart L, Gadue P, et al. BMP-4 is required for hepatic 
specification of mouse embryonic stem cell-derived definitive endoderm. Nat 
Biotechnol 2006;24:1402-1411
Page 21 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22
12. Panduro A, Shalaby F, Shafritz DA. Changing patterns of transcriptional and 
post-transcriptional control of liver-specific gene expression during rat 
development. Genes Dev 1987;1:1172-1182
13. Spear BT. Alpha-fetoprotein gene regulation: lessons from transgenic mice. 
Semin Cancer Biol 1999;9:109-116
14. Tilghman SM, Belayew A. Transcriptional control of the murine 
albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci U S 
A 1982;79:5254-5257
15. Matsunaga I, Shiro Y. Peroxide-utilizing biocatalysts: structural and functional 
diversity of heme-containing enzymes. Curr Opin Chem Biol 2004;8:127-132
16. Hay DC, Zhao D, Ross A, et al. Direct differentiation of human embryonic 
stem cells to hepatocyte-like cells exhibiting functional activities. Cloning 
Stem Cells 2007;9:51-62
17. Xu C, Inokuma MS, Denham J, et al. Feeder-free growth of undifferentiated 
human embryonic stem cells. Nat Biotechnol 2001;19:971-974
18. Gerrard L, Zhao D, Clark AJ, et al. Stably transfected human embryonic stem 
cell clones express OCT4-specific green fluorescent protein and maintain self-
renewal and pluripotency. STEM CELLS 2005;23:124-133
19. Hay DC, Sutherland L, Clark J, et al. Oct-4 knockdown induces similar 
patterns of endoderm and trophoblast differentiation markers in human and 
mouse embryonic stem cells. STEM CELLS 2004;22:225-235
Page 22 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23
20. Mitchell AM, Bridges JW, Elcombe CR. Factors influencing peroxisome 
proliferation in cultured rat hepatocytes. Arch Toxicol 1984;55:239-246
21. Gerrard L, Rodgers L, Cui W. Differentiation of human embryonic stem cells 
to neural lineages in adherent culture by blocking bone morphogenetic protein 
signaling. STEM CELLS 2005;23:1234-1241
22. McGrath KE, Koniski AD, Maltby KM, et al. Embryonic expression and 
function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 
1999;213:442-456
23. Costa RH, Grayson DR. Site-directed mutagenesis of hepatocyte nuclear 
factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal 
synergistic interactions with its enhancer region. Nucleic Acids Res 
1991;19:4139-4145
24. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal 
and postnatal donors. J Exp Med 2007;204:1973-1987
25. Asahina K, Fujimori H, Shimizu-Saito K, et al. Expression of the liver-
specific gene Cyp7a1 reveals hepatic differentiation in embryoid bodies 
derived from mouse embryonic stem cells. Genes Cells 2004;9:1297-1308
26. D'Amour KA, Agulnick AD, Eliazer S, et al. Efficient differentiation of 
human embryonic stem cells to definitive endoderm. Nat Biotechnol 
2005;23:1534-1541
Page 23 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
27. Rocken C, Licht J, Roessner A, et al. Canalicular immunostaining of 
aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. 
J Clin Pathol 2005;58:1069-1075
28. Smith JC, Price BM, Van NK, et al. Identification of a potent Xenopus 
mesoderm-inducing factor as a homologue of activin A. Nature 1990;345:729-
731
29. Vincent SD, Dunn NR, Hayashi S, et al. Cell fate decisions within the mouse 
organizer are governed by graded Nodal signals. Genes Dev 2003;17:1646-
1662
30. McLean AB, D'Amour KA, Jones KL, et al. Activin a efficiently specifies 
definitive endoderm from human embryonic stem cells only when 
phosphatidylinositol 3-kinase signaling is suppressed. STEM CELLS
2007;25:29-38
31. Jiang J, Au M, Lu K, et al. Generation of insulin-producing islet-like clusters 
from human embryonic stem cells. STEM CELLS 2007;25:1940-1953
32. Stanley LA, Horsburgh BC, Ross J, et al. PXR and CAR: nuclear receptors 
which play a pivotal role in drug disposition and chemical toxicity. Drug 
Metab Rev 2006;38:515-597
33. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the 
likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 
1997;32:210-258
Page 24 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25
34. Selden C, Shariat A, McCloskey P, et al. Three-dimensional in vitro cell 
culture leads to a marked upregulation of cell function in human hepatocyte 
cell lines--an important tool for the development of a bioartificial liver 
machine. Ann N Y Acad Sci 1999;875:353-363
35. Huang H, Hanada S, Kojima N, et al. Enhanced functional maturation of fetal 
porcine hepatocytes in three-dimensional poly-L-lactic acid scaffolds: a 
culture condition suitable for engineered liver tissues in large-scale animal 
studies. Cell Transplant 2006;15:799-809
36. Giuliano M, Lauricella M, Calvaruso G, et al. The apoptotic effects and 
synergistic interaction of sodium butyrate and MG132 in human 
retinoblastoma Y79 cells. Cancer Res 1999;59:5586-5595
37. Joseph J, Mudduluru G, Antony S, et al. Expression profiling of sodium 
butyrate (NaB)-treated cells: identification of regulation of genes related to 
cytokine signaling and cancer metastasis by NaB. Oncogene 2004;23:6304-
6315
38. Cai J, Zhao Y, Liu Y, et al. Directed differentiation of human embryonic stem 
cells into functional hepatic cells. Hepatology 2007;45:1229-1239
Page 25 of 42
ScholarOne Support: (434) 817-2040 ext. 167
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26
FIGURE LEGENDS
Figure 1.  A three-step protocol to differentiate hESCs to hepatocytes. (A) Schematic 
representation illustrating the three-stage procedure in differentiation of hESCs to 
hepatocytes. (B) Images showing sequential morphological changes from hESCs (H7) 
to hepatocytes through the definitive endoderm and hepatoblast during differentiation. 
NaBut: sodium butyrate; DMSO: dimethyl sulfoxide; SR: knockout serum 
replacement; HGF: hepatocyte growth factor; OSM: oncotatin M.
Figure 2. Progressive alteration of the gene expression pattern during the 
differentiation from hESCs (H7) to hepatocytes resembles that of liver development 
in vivo. RT-PCR (A & C) and Western blotting (B) showing progressive 
downregulation of undifferentiated cell gene expression, transient expression of 
mesendoderm markers and upregulation of hepatocyte genes expression. Stages and 
days in differentiation are as indicated. (D) Flow cytometry analysis showing increase 
of CXCR4 expressing cells during stage 1 differentiation. ES: hES cells; F: fetal liver 
RNA; A: adult liver RNA. *: positive control for Pax6 from hESC-derived neural 
progenitor.
Figure 3. Characterisation of the hESCs-derived hepatocytes. (A)
Immunocytochemistry showing expression of various markers during differentiation 
process. The labels on the right upper corner of each image represent day (d) and 
stage (st) of their differentiation and the label on the right lower corner represent 
antibodies used. Scale bar represents 100µm in a-d and 50µm in e & f. (B)
Immunocytochemistry showing expression of CK18, CK19 and CD13 in hESC-
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derived hepatocytes (a, b, & d respectively). Negative controls were performed with 
corresponding IgG and representative is shown in c. CD13 showed no staining in 
Hep3B cells (e). Scale bar represents 50µm.
Figure 4.  Comparison of the effect of activin A and sodium butyrate (NaB) in the 
differentiation of hESCs (H7) to definitive endoderm and in the further differentiation 
to hepatocyte. (A) Phase-contrast images of hESCs treated with activin A or NaB
alone or with combined activin A and NaB for three days (upper panel), then 
transferred to DMSO containing medium for further 4 days (lower panel). (B)
Comparison of gene expression with these treatments during the first stage of 
differentiation.
Figure 5. Functional test of hESC-derived hepatocytes. (A) hESC-derived 
hepatocytes produce and secrete plasma proteins, fibrinogen, fibronectin and alpha-2 
macroglobulin, which are significant higher in comparison to their original hESCs, * 
and ** representing P<0.005 and P<0.01 by student t test. (B) hESC-derived 
hepatocytes express cytochrome p450 reductase (CPR), CYP3A of P450 family and 
c-met. They also exhibit evident glycogen storage. Scale bar represent 100µm in 
glycogen and 50µm in the rest.
Figure 6.  Cytochrome p450 isozymes in hESC-derived hepatocytes (hESC-HC). (A)
Western blotting showing protein expression of CYP3A (CYP3A4, CYP3A5, 
CYP3A7) and CYP2D6 in hESCs and hESC-HC from 2 experiments. (B) RT-PCR 
showing CYP3A4, CYP3A7 and CYP2C9 and CYP2C19 expression in hESC, hESC-
derived definitive endoderm (DE, end of stage 1), hESC-derived hepatocytes (hESC-
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HC), fetal and adult liver. (C). Basal metabolism of p450 substrates. The p450 
substrates as indicated were administered to the cells and their metabolites were 
detected by mass spectrometry and normalised over alanine aminotransferase (ALT). 
The p values were calculated by student t test between HepG2 cells and hESC-HC. 
(D). Induction of CYP3A4 by rifampicin in both hESC-HC and HepG2 cells. The 
cells were treated with rifampicin or vehicle, DMSO, for 72 hours prior CYP3A4 
substrate midazolam administration. The metabolite 1’hydroxymidazolam (1’OH-
Midazolam) was measured by mass spectrometry and normalised over alanine 
aminotransferase (ALT). The p value was calculated in hESC-HC by student t test 
between control (DMSO) and rifampicin treatment.
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SUPPLEMENTAL FIGURE LEGENDS
Figure 7. (A) High magnification image of hESC-derived hepatocytes. (B) hESC-
derived hepatocytes in culture at day 24 of differentiation showing deteriorated 
hepatocytes with increased fiber-producing cells. (C) Periodic Acid Schiff (PAS) 
staining on fibroblast cells showing no glycogen storage.
Figure 8. Differentiation of H1 hESC line showing a similar gene expression pattern 
to H7. (A & B). Gene expression profile of H1 during differentiation (A) and at the 
first stage of differentiation with activin or NaBut alone or with combined treatment 
(B). (C). Generation and secretion of plasma protein in H1 cells.
Figure 9. RT-PCR showing CYP7A1 expression in hESC, hESC-derived hepatocytes 
(hESC-HC) and fetal and adult liver tissues.
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Suppl. Table 1. PCR primers and conditions
Name Forward primer (5'-3') Reverse primer (5'-3') size Ta (°C)
AFP AGAACCTGTCACAAGCTGTG GACAGCAAGCTGAGGATGTC 675 bp 55
ALB CCTTTGGCACAATGAAGTGGGTAACC CAGCAGTCAGCCATTTCACCATAGG 354 bp 55
ApoF GGAAGCGATCAAACCTACCA ATCAGCCTGACAACCAGCTT 347 bp 55
-Actin TCACCACCACGGCCGAGCG TCTCCTTCTGCATCCTGTCG 350 bp 61
Brachyury GTGACCAAGAACGGCAGGAGG TGTTCCGATGAGCATAGGGGC 706 bp 61
CAR CAGCAAACACCTGTGCAACTG AAGGGCTGGTGATGGATGAA 145 bp 57
CK7 TCGCTGAGGTCAAGGCACAG CACTCCTCAGCCTCGGCAAT 241 bp 59
CK18 GGGCCCAATATGACGAGCTG AGCAGGATCCCGTTGAGCTG 270 bp 59
CK19 CTCCCGCGACTACAGCCACT TCAGCTCATCCAGCACCCTG 211bp 59
CXCR4 CACCGCATCTGGAGAACCA GCCCATTTCCTCGGTGTAGTT 79 bp 55
Cyp2C19 ATGTTTGCTTCTCCTTTCAA CCAAAATATCACTTTCCATAA 700 bp 49
Cyp2C9 ACATTGACCTTCTCCCCACCAGCC CAAATCCATTGACAACTGGAGTGG 356 bp 57
Cyp3A4 CCTTACATATACACACCCTTTG GGTTGAAGAAGTCCTCCTAAGCT 169 bp 50
Cyp3A7 CTATGATACTGTGCTACAGT TCAGGCTCCACTTACGGTCT 455 bp 50
Cyp7A1 GTGCCAATCCTCTTGAGTTCC ACTCGGTAGCAGAAAGAATACATC 397 bp 55
FOXA2 AGATGGAAGGGCACGAGC CAGGCCGGCGTTCATGTT 88 bp 56
GATA4 CATCAAGACGGAGCCTGGCC TGACTGTCGGCCAAGACCAG 218 bp 60
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GATA6 CCATGACTCCAACTTCCACC ACGGAGGACGTGACTTCGGC 213 bp 57
GSC GAGGAGAAAGTGGAGGTCTGGTT CTCTGATGAGGACCGCTTCTG 71 bp 61
HNF1 TACACCACTCTGGCAGCCACACT CGGTGGGTACATTGGTGACAGAAC 114 bp 59
HNF1 TCACAGATACCAGCAGCATCAGT GGGCATCACCAGGCTTGTA 79 bp 55
HNF4 CTGCTCGGAGCCACCAAGAGATCCATG ATCATCTGCCACGTGATGCTCTGCA 370 bp 55
HNF6 CGCTCCGCTTAGCAGCAT GTGTTGCCTCTATCCTTCCCAT 61 bp 55
Mix1 GGTACCCCGACATCCACTT GCCTGTTCTGGAACCATACCT 87 bp 57
Nanog AGCCTCTACTCTTCCTACCACC TCCAAAGCAGCCTCCAAGTC 278 bp 60
Oct4 GACAACAATGAAAATCTTCAGGAGA TTCTGGCGCCGGTTACAGAACCA 218 bp 60
Pax6 AACAGACACAGCCCTCACAAACA CGGGAACTTGAACTGGAACTGAC 275 bp 60
PXR GGAGAAGTCGGAGCAAAGAA AGCTCCCTGATCATCATCCGC 517 bp 58
SOX17 CCAGAATCCAGACCTGCACAA CTCTGCCTCCTCCACGAA 100 bp 57
TAT ACTGTGTTTGGAAACCTGCC GCAGCCACTTGTCAGAATGA 188 bp 55
TERT AGC GAC TAC TCC AGC TAT G GTT CTT GGC TTT CAG GAT GG 304 bp 61
TO GGCAGCGAAGAAGACAAATC TCGAACAGAATCCAACTCCC 218 bp 55
TTR GCCGTGCATGTGTTCAGAAAG GACAGCCGTGGTGGAATAGGA 258 bp 58
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Suppl. Table 2. List of antibodies used.
Primary antibodies
Antigen Type Company Dilution
AAT Mouse Mono QED Bioscience 1/2000 (WB)
AFP Mouse Mono SIGMA 1/2000 (WB); 1/500 (ICC)
ALB Mouse Mono SIGMA 1/2000 (WB); 1/500 (ICC)
-Actin Mouse Mono SIGMA 1/10000 (WB)
Brachyury Goat Poly R and D Systems 1/20 (ICC)
CD13 Mouse Mono Invitrogen 1/50 (ICC)
CK18 Mouse Mono Invitrogen 1/50 (ICC)
CK19 Mouse Mono Invitrogen Ready made
C-MET Rabbit Poly Santa Cruz 1/100 (WB); 1/25 (ICC)
CPR Rabbit Poly ABCAM 1/500 (ICC)
CXCR4 - PE Mouse Mono R and D Systems 1:3.5
CYP3A Sheep poly U. of Dundee 1/1000
CYP2D6 Sheep poly U. of Dundee 1/1000
E-CAD Mouse Mono DAKO 1/100 (WB)
FOXA2 Goat Poly R and D Systems 1/200 (WB); 1:20 (ICC)
HEPPAR1 Mouse Mono DAKO 1/25 (ICC)
HNF4a Rabbit Poly Santa Cruz 1/200 (WB); 1/100 (ICC)
OCT-4 Mouse Mono Santa Cruz 1/200 (WB)
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Secondary antibodies
Type Company Dilution
Goat anti –mouse IgG HRP DAKO 1/2,500
Goat anti-rabbit IgG HRP DAKO 1/2,500
Rabbit anti goat IgG HRP DAKO 1/2,500
Goat anti-sheep Santa Cruz 1/2,500
Alexa Fluor 488 goat anti-mouse Molecular Probes 1/500
Alexa Fluor 488 goat anti-rabbit Molecular Probes 1/500
Alexa Fluor 568 goat anti-mouse Molecular Probes 1/500
Alexa Fluor 488 donkey anti-goat Molecular Probes 1/500
Alexa Fluor 488 donkey anti-sheep Molecular Probes 1/500
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